Peter A. Fratarcangelo, Ph.D. - CEO
Peter
Fratarcangelo has
more than 25 years
experience in the
clinical research
of Rx, OTC, & Rx
OTC
switch compounds.
As CEO of International
HealthCare, former
CEO and Director
of Research at International
Pharmaceutical Research
(a mid-size CRO),
Peter has guided
the research of more
than 150 compounds.
He has been successful
in designing, coordinating
and implementing
entire clinical programs
for 9 RxOTC
switches & 7 Rx - NDA programs, 3 NCE agents, one biologic
and two medical devices. As
Director of Research,
Peter successfully
guided the clinical
development and provided
the pivotal research
for many important
new drugs now on
the market. Samples
of such are:
| Pepcid-AC® |
Zantac-75® |
Tagamet-HB® |
Axid-AR® |
| Imodium-AD® |
Carafate® |
Gyne-Lotrimin® |
Mycelex® |
| Nicorette Gum® |
Children's Motrin® |
Eno® |
Robaxin® |
| Lorabid® |
Preparation-H® |
Maalox® |
Massengill® |
| Zofran® |
Imitrex® |
|
|
| Children's & Extra Strength Tylenol® |
| Crest Sensitive®, Promise® and Aqua-Fresh Sensitive® toothpaste |
Peter
has presented more than
forty papers and clinical
reports at symposiums
and conferences covering
the wide range of therapeutic
areas evident in his
research referenced above.
Peter is also a frequent
speaker at International
Research Conferences,
training the attendees
on the design of clinical
studies for RxOTC
Switching, proper clinical
site management and Good
Clinical Practices. Before
starting his CRO in 1984,
Peter worked as Associate
Director of Rx Clinical
Research in the New Drug
Development Department
at Pfizer Pharmaceuticals
and in the OTC arena
as Associate Director-Personal
Products at Richardson-Vicks,
Inc. Peter holds a B.S. degree
from Manhattan College,
an MS from NYU, and a
Ph.D. from CPU. He is
an associate member of
the CHPA, a member of
the Drug Information
Association and a charter
member of the National
Institute for Infectious
Disease.
William K. Tobin - President
Bill Tobin has been conducting and managing clinical
trials for drugs, biologics, tissue and medical devices
in a wide
range of therapeutic areas for over 10 years. Prior to
joining International HealthCare, Bill served as Clinical
Project Manager at Purdue Pharma, LLP in Stamford, CT.
While at Purdue he managed a newly developed local anesthetic
product and later was promoted to manage all clinical trials
for the clinically acclaimed long acting analgesic, OxyContin.
Initially entering the medical research field as a Clinical
Research Associate at International Pharmaceutical Research,
a CRO based in Norwalk, CT, Bill became key to the company's
growth to over 100 clinical scientists, SAS programmers
and statisticians. His role and responsibilities included
project planning, protocol development, investigator selection,
project implementation and data analysis for many successful
NDA programs. He also held positions as Project Manager
and Associate Director of New Business Development. Bill
has the unique experience as a clinical program manager
for both a large Pharma and a mid-size CRO and has managed
successful large-scale domestic and international programs.
With experience and expertise as two key elements in achieving
success, Bill delivers these critical attributes in every
project he manages.
Bill
is a member of the Drug Information
Association, and the Association
of Clinical Research Professionals. He maintains his state-of-the-art
knowledge of Good Clinical
Practices through continuous
industry provided education such
as: ACRP Certifications,
Techniques of Peripheral Vascular Intervention,
Barnett Management and Monitoring
Training, Barnett Device Training, and Barnett Trial Management
Training. A
graduate of Providence College
with a B.S. in biology, Bill
has completed his M.P.H.
in epidemiology at New York
Medical College.
